{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 4\u00b2 (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'Pharmacokinetics', 'X11', 'X12', 'X13', 'X14', 'infusion (EOI), and 1-hour (+5 minutes) post EOI. On subsequent dosing days, vital signs', 'PK5,', 'must be assessed at pre-dose (within 30 minutes prior to SOI), within +5 minutes of EOI. On', 'Anti-drug', 'days where vital sign time points align with PK sampling time points, vital signs must be', 'X', 'X', 'antibodies5, 15', 'assessed prior to PK samples being drawn. On days where vital signs are measured multiple', 'Disease Evaluation', 'times, temperature does not need to be repeated unless clinically indicated.', 'Response', 'X', '7.', 'Refer to Table 14 for a comprehensive list of lab tests that must be collected for all', 'assessment16', 'participants. If labs are completed within 72 hours prior to the first dose, this assessment need', 'Skeletal Survey 17', 'As clinically', 'not be repeated on C1D1.', 'indicated', 'Week 13, 25,', '8.', 'Albumin / creatinine ratios (spot urine from first void) at, C1, and every other cycle thereafter', '37, 49, and', '(C3, C5, C7, etc.) (use local labs; use central labs if local not available)', 'then every', '9.', 'Perform only in women of child-bearing potential. A serum pregnancy test must be performed', '12 weeks', 'at screening, and subsequent pregnancy tests may be either serum or urine. If test is', 'Imaging for', 'within the', 'completed within 72 hours prior to the first dose, this assessment need not be repeated on', 'Extramedullary', 'first 12', 'C1D1. For questionable cases of whether a participant is of non-child bearing potential, obtain', 'disease\u00b9 18', 'months;', 'follicle stimulating hormone (FSH) and estradiol. See Section 6.1, Section 9.2.8, and', 'thereafter', 'Appendix 5 for more details.', 'only if', 'clinically', '10. ECGs on dosing days: Triplicate ECGs to be performed at predose (within 30 minutes prior to', 'indicated', 'SOI) and EOI (within 5 minutes prior to EOI) at cycles 1, 2, 3, 6, 9 and 12. Additional triplicate', 'PET/CT upon', 'ECGS to be performed at 24 h + 2h after SOI on Day 1 of Cycle 1 and Cycle 3 and on Day 4', 'Once after', 'achieving CR or', 'CR or sCR', '(+1 day) and on any day from Day 8 to Day 15 in Cycle 1 and Cycle 3. Single ECGs predose', 'sCR19', 'at all other cycles.', 'UPEP (Urine', 'ECG recordings should be made after at least 10 minutes rest and collected 2 minutes apart.', 'Protein', 'X', 'On days where ECG time points align with PK sampling time points, ECGs must be performed', 'Electrophoresis) 24', 'prior to PK samples being drawn. ECGs on Day 4 and Day 8-15 in Cycle 1 and Cycle 3 should', 'hr. urine collection', '24']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Q3W', 'Cycle', 'Cycle', '1 &', '1 &', 'starting', 'Study', 'Cycle 1,', 'Wk 4\u00b2 (to be', 'Cycle 2-', 'Assessments', 'Cycle', 'Cycle', 'CX with', 'Notes', 'Day 11', '3 Day', 'performed', '3, Day', 'dosing 2', '4', '8-15', 'regardless', 'of dosing)', 'By central', 'be collected at a similar time of day as the SOI on Cycle 1 Day 1 (+2 h). ECGs will be collected', 'lab if UPEP', 'and stored centrally and may be reviewed by an independent central reviewer. See SRM for', 'is negative,', 'details on collection regarding ECGs.', 'at the time of', 'first', '11. PK samples to be taken in all participants for GSK2857916 measurement during Cycle 1, Day', 'Urine', 'achieving CR', '1 and Cycle 3, Day 1 at the following study times: predose (within 30 minutes prior to SOI), at', 'Immunofixation', 'then perform', 'EOI (+5 min), at 2 h (+15 min) after SOI, and at 24 h (2 hrs) after SOI.', 'every 3', '12. PK samples to be taken for GSK2857916 measurement C1D4 and C3D4 (+1 day): one', 'weeks until', 'sample after ECG collection.', 'suspected', 'PD after CR', '13. One PK sample to be taken for GSK2857916 measurement in Cycle 1 and Cycle 3 after ECG', 'or sCR.', 'collection on any day from Day 8 to Day 15. If dosing is delayed at Cycle 2 or Cycle 4, a PK', 'SPEP (Serum', 'sample should be drawn 21 days post dose (Day 22 +2 days) in Cycle 1 and Cycle 3.', 'Protein', 'X', '14. PK samples to be taken on Cycle 3, Day 1 at the following study times: predose (within 30', 'Electrophoresis)', 'minutes prior to SOI), at EOI (+5 min), at 2 h (+15 min) after SOI, and at 24 h (2 hrs) after', 'By central', 'SOI. At C2, C4, C6, C9, and C12, PK samples to be taken at predose (within 30 minutes prior', 'lab if SPEP', 'to SOI) and at EOI (+5 min). Every 6 subsequent cycles (e.g., C18, C24, etc.) at predose', 'is negative at', '(within 30 minutes prior to SOI).', 'the time of', 'first', '15. Anti-drug antibodies should be collected prior to the dose at C2, C6, C9, C12, and every 6', 'Serum', 'achieving CR', 'cycles thereafter (C18, C24, etc.) until end of treatment (dosing days only) with the PK sample', 'Immunofixation', 'then perform', '16. Response assessment must be conducted every 3 weeks based on disease laboratory tests', 'every 3', 'and imaging (if applicable) as outlined in this table. Response evaluation will be performed', 'weeks until', 'according to the IMWG (Uniform Response Criteria for Multiple Myeloma 2016). Central', 'suspected', 'laboratory results for all disease response assessments will be shared with the Independent', 'PD after CR', 'Review Committee (IRC)', 'or sCR.', 'Serum Kappa,', '17. Only if clinically indicated or if worsening clinical symptoms suggest skeletal PD.', 'Lambda free Light', 'X', '18. Imaging is only required for participants with extramedullary disease (CT, MRI, or PET/CT can', 'chain, FLC ratio', '25']\n\n###\n\n", "completion": "END"}